Oric Pharmaceuticals, Inc. financial data

Symbol
ORIC on Nasdaq
Industry
Pharmaceutical Preparations
Location
240 E. Grand Ave., 2 Nd Floor, South San Francisco, CA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.43K % -4.34%
Debt-to-equity 9.39 % -10.1%
Return On Equity -40.2 % +1.35%
Return On Assets -36.7 % +0.41%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 70.5M shares +29.4%
Common Stock, Shares, Outstanding 67.7M shares +24.1%
Entity Public Float 415M USD +140%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 70.3M shares +54.1%
Weighted Average Number of Shares Outstanding, Diluted 70.3M shares +54.1%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 27.3M USD +13.2%
Operating Income (Loss) -125M USD -27%
Nonoperating Income (Expense) 14.3M USD +142%
Net Income (Loss) Attributable to Parent -111M USD -19.7%
Earnings Per Share, Basic -1.75 USD/shares +19.7%
Earnings Per Share, Diluted -1.75 USD/shares +19.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49.8M USD -51.9%
Assets, Current 295M USD +9.78%
Property, Plant and Equipment, Net 2.88M USD -11.4%
Operating Lease, Right-of-Use Asset 9.14M USD -16.8%
Other Assets, Noncurrent 9.3M USD -12.5%
Assets 329M USD +12.7%
Accounts Payable, Current 2.31M USD -27.6%
Accrued Liabilities, Current 17.2M USD +51.9%
Liabilities, Current 19.5M USD +34.4%
Operating Lease, Liability, Noncurrent 7.46M USD -21%
Other Liabilities, Noncurrent 6.97M USD -17.9%
Liabilities 26.5M USD +15.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -256K USD +54.9%
Retained Earnings (Accumulated Deficit) -492M USD -29.1%
Stockholders' Equity Attributable to Parent 302M USD +12.5%
Liabilities and Equity 329M USD +12.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.2M USD -46.3%
Net Cash Provided by (Used in) Financing Activities 125M USD
Net Cash Provided by (Used in) Investing Activities -61.9M USD -584%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 67.7M shares +24.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 33M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 50.3M USD -51.7%
Deferred Tax Assets, Valuation Allowance 133M USD +31.1%
Deferred Tax Assets, Gross 136M USD +29.6%
Operating Lease, Liability 10.2M USD -15.6%
Depreciation 261K USD +3.16%
Payments to Acquire Property, Plant, and Equipment 218K USD -29.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -110M USD -20.2%
Lessee, Operating Lease, Liability, to be Paid 12M USD -18.7%
Property, Plant and Equipment, Gross 9.82M USD +2.76%
Operating Lease, Liability, Current 2.77M USD +2.44%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.68M USD -6.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.85M USD +3.48%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.81M USD -32.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.68M USD +0.04%
Deferred Tax Assets, Operating Loss Carryforwards 75.8M USD +18.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 2.81M USD +29.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.77M USD +3.51%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.68M USD -15.8%
Share-based Payment Arrangement, Expense 17.7M USD +28%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%